News Categories
Resources For Living
Mesothelioma Forum
Legal Help Blog
Find a Doctor Near You
About Mesothelioma
Latest News
- Leading Mesothelioma Researcher Now Leads the Canc...
- $2.25 Million Awarded in Mesothelioma Death
- U.S. and China Companies Join Forces in Manufactur...
- Clinical Trial Spotlight: Pemetrexed (ALIMTA) Plu...
- Wake Forest School of Medicine and FirstHealth of ...
- Mesothelioma Patients Eligible for Air Transportat...
- Mesothelioma Awareness Day Proposed as National Ev...
- Tougher Toxic Chemical Legislation Being Considere...
- Texas Cancer Center Offers Hope to Mesothelioma Pa...
- Alimta Extends Life of Lung Cancer Patients
News Archives
- April 2007
- May 2007
- June 2007
- July 2007
- August 2007
- September 2007
- October 2007
- November 2007
- December 2007
- January 2008
- February 2008
- March 2008
- April 2008
- May 2008
- June 2008
- July 2008
- August 2008
- September 2008
- October 2008
- November 2008
- December 2008
- January 2009
- February 2009
- March 2009
- April 2009
- May 2009
- June 2009
- July 2009
- August 2009
- September 2009
- October 2009
- November 2009
- December 2009
- January 2010
- February 2010
- March 2010
Tuesday, October 27, 2009
In September the National Institutes of Health announced the winners of their awards designated to encourage high-risk research and innovation. They have awarded $348 million to "encourage investigators to explore bold ideas that have the potential to catapult fields forward and speed the translation of research into improved health."The awards fall under three research programs supported by the NIH Common Fund’s Roadmap for Medical Research. The NIH Director’s Transformative R01 (T-R01) Awards - new in 2009, Pioneer Awards, and New Innovator Awards, are funded through the 2006 NIH Reform Act which emphasizes innovation and risk taking, and the American Recovery and Reinvestment Act.
One of the T-RO1 winners, Sanford Markowitz, MD, PhD, of Case Western Reserve University School of Medicine, is undertaking research for "identifying inborn genetic susceptibility to development of cancer metastasis." Most deaths from cancer are a result of metastasis, and Markowitz is setting out to determine why some people are resistant to the spread, while others have an inborn genetic predisposition to the spread of the disease.
Markowitz believes the results of this study will "be felt in the identification of entirely new biological pathways that will be key to cancer management, to cancer prognosis, and to developing new and more effective anti-cancer therapies."
The researchers are given the flexibility to work in large, complex teams if the complexity of the research problem demands it. The projects are funded over a five year period.
For a listing of all 2009 Transformative R01 Award Recipients see the NIH website.
Labels: cancer, Research News
posted by Nancy Meredith at 9:43 AM
